Brooklyn ImmunoTherapeutics (BTX) Climbs 9.90% on August 5

Equities Staff  |

Brooklyn ImmunoTherapeutics Inc (NYSE: BTX) has climbed $0.0495 (9.90%) and sits at $0.55, as of 11:47:42 est on August 5.

321,504 shares have traded hands.

The Company rose 5.20% over the last 5 days and shares have fallen 11.22% over the last 30 days.

Brooklyn ImmunoTherapeutics expects its next earnings on 2022-08-15.

For technical charts, analysis, and more on Brooklyn ImmunoTherapeutics visit the company profile.

About Brooklyn ImmunoTherapeutics Inc

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

To get more information on Brooklyn ImmunoTherapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Brooklyn ImmunoTherapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content